Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2018 | Promising treatments in CTCL

Pierluigi Porcu • 12 Sep 2018
SOHO 2018
Cutaneous T-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Rare Diseases T-Cell Lymphoma Antibodies Pembrolizumab

With new targets identified over the past few years, the development of precision medicine has expanded significantly. Speaking from the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting in Houston, TX, Pierluigi Porcu, MD, from, Sidney Kimmel Cancer Center, Philadelphia, PA, explores the many new drugs that are currently being trialed. Dr Porcu discusses monoclocnal antibody IPH4102, which has shown promising results in Phase I trials as well as oligonucleotide miR-155 and immunotherapies including pembrolizumab.

More from Pierluigi Porcu

2:49
Exciting research in CTCL: genomics, the tumor microenvironment and the potential role of MRD
Pierluigi Porcu • 16 Jun 2023
3:00
The current SOC in CTCL: skin-directed therapy, systemic therapy & clinical challenges
Pierluigi Porcu • 16 Jun 2023
3:18
Lacutamab in patients with advanced mycosis fungoides: results from the TELLOMAK trial
Pierluigi Porcu • 16 Jun 2023
4:17
Nanatinostat and valganciclovir for EBV-associated lymphoma
Pierluigi Porcu • 6 Dec 2020

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals